Search results for "cardiomyopathies"

showing 10 items of 62 documents

Identification of a novel compound heterozygote SCO2 mutation in cytochrome c oxidase deficient fatal infantile cardioencephalomyopathy

2006

UNLABELLED Fatal infantile cardioencephalomyopathy (OMIM No. 604377) is a disorder of the mitochondrial respiratory chain and is characterised by neonatal progressive muscular hypotonia and cardiomyopathy because of severe Cytochrome c oxidase deficiency. Here we report a novel mutation in the Cytochrome c oxidase assembly gene SCO2 in an infant with fatal infantile cardioencephalomyopathy despite normal initial metabolic screening. CONCLUSION In newborns with unexplained muscular hypotonia and cardiomyopathy genetic testing of mitochondrial respiratory chain disorders might be helpful to establish a final diagnosis and guide treatment decisions.

Heterozygotemedicine.medical_specialtyPathologyCardiomyopathyCytochrome-c Oxidase DeficiencyCompound heterozygositymedicine.disease_causeMitochondrial ProteinsFatal OutcomeMitochondrial EncephalomyopathiesInternal medicinemedicineHumansCytochrome c oxidaseGeneGenetic testingMutationMuscular hypotoniamedicine.diagnostic_testbiologybusiness.industryInfantGeneral Medicinemedicine.diseaseEndocrinologyMitochondrial respiratory chainMutationPediatrics Perinatology and Child Healthbiology.proteinFemaleCardiomyopathiesCarrier ProteinsbusinessMolecular ChaperonesActa Paediatrica
researchProduct

In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival

2018

BackgroundCirrhotic cardiomyopathy (CCM) refers to cardiac dysfunction in patients with liver cirrhosis, in the absence of other known cardiac disease.MethodsControl group and patients diagnosed of liver cirrhosis without known cardiac disease or hepatocellular carcinoma were enrolled for this clinical observation study. Patients with diabetes mellitus, hypertension were excluded. Absolute global longitudinal strain, one-point carotid pulse wave velocity (one-point PWV) and various parameters were measured in resting status.ResultsThere were 29 participants in the control group and 80 patients in the liver cirrhosis group. 27.8% of cirrhotic patients presented with normal systolic but abnor…

Liver CirrhosisMaleRNA virusesCirrhosisEtiologySocial SciencesHepacivirus030204 cardiovascular system & hematologyMathematical and Statistical Techniques0302 clinical medicineMedicine and Health SciencesPsychologyCardiac OutputPulse wave velocityPathology and laboratory medicineMultidisciplinaryHepatitis C virusLiver DiseasesQStatisticsRHepatitis CMiddle AgedMedical microbiologyHepatitis CAddictsCirrhosisHepatocellular carcinomaVirusesPhysical SciencesCardiologyMedicineRegression AnalysisFemale030211 gastroenterology & hepatologyPathogensCardiomyopathiesResearch ArticleAdultHepatitis B virusmedicine.medical_specialtyDeath RatesScienceCardiologyDiastoleAddictionGastroenterology and HepatologyPulse Wave AnalysisResearch and Analysis MethodsMicrobiology03 medical and health sciencesPopulation MetricsInternal medicineDiabetes mellitusmedicineHumansAlcoholicsStatistical MethodsAgedHepatitisBiology and life sciencesFlavivirusesPopulation Biologybusiness.industryOrganismsViral pathogensmedicine.diseaseHepatitis virusesCirrhotic cardiomyopathyMicrobial pathogensbusinessMathematicsPLOS ONE
researchProduct

QT Indexes in Cirrhotic Patients: Relationship with Clinical Variables and Potential Diagnostic Predictive Value.

2015

Background and Aims A wide spectrum of cardiovascular changes characterizes cirrhosis, ranging from subclinical alterations to hyperkinetic syndrome. We looked for ECG markers of ventricular repolarization in a population of patients with cirrhosis in comparison to patients without cirrhosis and we investigated the relationship between these and other clinical and laboratory variables. Methods In 149 patients with cirrhosis and 152 controls, we measured QT maximum interval (QTmax), QT corrected interval (QTc), QT minimum interval (QTmin), QT dispersion (QTdisp), QT peak and T peak-to-end (TpTe). Results In subjects with cirrhosis, in comparison with controls, we observed a higher mean QTmax…

Liver CirrhosisMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCirrhosisPopulationQT cirrhosis dispersionQT intervalElectrocardiographyPredictive Value of TestsInternal medicinemedicineHumanseducationSubclinical infectionAgedRetrospective Studieseducation.field_of_studyReceiver operating characteristicProportional hazards modelbusiness.industryArrhythmias CardiacGeneral MedicineMiddle Agedmedicine.diseasePredictive valueBlood pressureROC CurveCardiologyFemalebusinessCardiomyopathiesArchives of medical research
researchProduct

Cardiac involvement in patients with cirrhosis: a focus on clinical features and diagnosis

2016

Cirrhotic heart has been traditionally considered protected from cardiovascular disease, even if a large amount of literature has recently shown that patients affected by chronic liver disease are exposed to cardiovascular events, as well. Since the first recognition of cardiac involvement in cirrhosis, all published studies explain that decompensated cirrhotic patients suffer from haemodynamic changes, currently known as hyperdynamic syndrome, which finally lead to cirrhotic cardiomyopathy. This is defined by the presence of a subclinical systolic dysfunction unmasked under stress conditions, impaired diastolic function and electrophysiological abnormalities, in the absence of any known ca…

Liver Cirrhosismedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaHemodynamicsDisease030204 cardiovascular system & hematologyChronic liver diseaseGastroenterology03 medical and health sciencesElectrocardiography0302 clinical medicineSerum biomarkersInternal medicinemedicineHumansIn patientSubclinical infectioncardiac function cardiomyopathy cirrhosisbusiness.industryGeneral Medicinemedicine.diseasePrognosisMagnetic Resonance ImagingCirrhotic cardiomyopathyEchocardiography Doppler030211 gastroenterology & hepatologyCardiology and Cardiovascular MedicinebusinessCardiomyopathiesBiomarkers
researchProduct

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

2017

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothel…

Male0301 basic medicineendocrine system diseasesDiabetic CardiomyopathiesFPS-ZM1 RAGE inhibitorClinical BiochemistryAorta ThoracicRAGE receptor for AGEICAM-1 intercellular adhesion molecule-1ECL enhanced chemiluminescence030204 cardiovascular system & hematologyDPP-4 dipeptidyl peptidase-4medicine.disease_causeTNF-α tumor necrosis factor-αBiochemistryeNOS endothelial •NO synthase (type 3)0302 clinical medicineGlucosidesecSOD extracellular superoxide dismutaseInsulin-Secreting CellsCCL-2 see MCP-1HyperlipidemiaHyperinsulinemiaGTN glyceryl trinitrate (nitroglycerin)IFN-γ interferon-γDHE dihydroethidineEndothelial dysfunctionEndothelial dysfunctionIL-6 interleukin-6lcsh:QH301-705.5HO-1 heme oxygenase-1lcsh:R5-920ICAM-1NG normoglycemiaDiabetesNox catalytic subunit of NADPH oxidaseSGLT2 inhibitorβ-cell contentL-012 8-amino-5-chloro-7-phenylpyrido[34-d]pyridazine-14-(2H3H)dione sodium saltChIP chromatin immunoprecipitationC-Reactive ProteinCRP C-reactive proteinAGE advanced glycation end productsHbA1c glycohemoglobinlcsh:Medicine (General)Research PaperZucker diabetic fatty ratsmedicine.medical_specialtyDMSO dimethylsulfoxideMCP-1 monocyte-chemoattractant-protein-1qRT-PCR quantitative reverse transcription polymerase chain reactionZDF Zucker diabetic fatty (rat)Low-grade inflammation03 medical and health sciencesROS reactive oxygen speciesSodium-Glucose Transporter 2Physiology (medical)Internal medicineDiabetes mellitusPKC protein kinase CEmpagliflozinmedicineAnimalsHypoglycemic AgentsBenzhydryl CompoundsCOX2 cyclooxygenase-2SGLT2i SGLT2 inhibitorSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinACh acetylcholinebusiness.industryOrganic Chemistrynutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseH2K9me2 histone3 lysine9 dimethylationRatsRats ZuckerDHFR dihydrofolate reductaseSGLT2 sodium-glucose co-transporter-2Oxidative StresssGC soluable guanylyl cyclaseGlucose030104 developmental biologyEndocrinologylcsh:Biology (General)ALDH-2 mitochondrial aldehyde dehydrogenaseEndothelium VascularAGE/RAGE signalingHG hyperglycemiabusinessOxidative stressRedox Biology
researchProduct

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A…

2016

Summary Objective In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as dia…

MaleCaptoprilDiabetic CardiomyopathiesMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineDiabetes mellitusRamiprilRetrospective StudieCardiovascular DiseaseMedicinePharmacology (medical)030212 general & internal medicineMyocardial infarctionDiabetic CardiomyopathieRandomized Controlled Trials as TopicAspirinLeft ventricular dysfunctionGeneral MedicineAcetyl salicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Diabetes mellitus; Left ventricular dysfunction; Ramipril; Zofenopril; Cardiology and Cardiovascular Medicine; Pharmacology (medical); PharmacologyMiddle AgedZofenoprilAcetyl salicylic acidCardiovascular DiseasesCardiologyPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugHumanRamiprilmedicine.medical_specialtyDiabetes mellituSystoleAcute myocardial infarctionZofenopril03 medical and health sciencesDiabetes mellitusInternal medicineHumansAgedRetrospective StudiesPharmacologyAspirinbusiness.industryPlatelet Aggregation InhibitorAngiotensin-Converting Enzyme Inhibitormedicine.diseasechemistryAngiotensin-converting enzyme inhibitorbusinessMacePlatelet Aggregation Inhibitors
researchProduct

Egg consumption and cardiovascular disease according to diabetic status: The PREDIMED study.

2015

BACKGROUND: Eggs are a major source of dietary cholesterol and their consumption has been sometimes discouraged. A relationship between egg consumption and the incidence of cardiovascular disease (CVD) has been suggested to be present exclusively among patients with type2 diabetes. AIMS: To assess the association between egg consumption and CVD in a large Mediterranean cohort where approximately 50% of participants had type 2 diabetes. METHODS: We prospectively followed 7216 participants (55-80 years old) at high cardiovascular risk from the PREDIMED (PREvención con DIeta MEDiterránea) study for a mean of 5.8 years. All participants were initially free of CVD. Yearly repeated measurements o…

MaleDiabetic CardiomyopathiesEggsHealth StatusSistema cardiovascular -- MalaltiesType 2 diabetes030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineDiet MediterraneanCohort Studies0302 clinical medicineRisk FactorsDiet Diabetic030212 general & internal medicineProspective StudiesProspective cohort studyDiet Fat-RestrictedAged 80 and overOusNutrition and DieteticsDiabetisMediterranean RegionIncidence (epidemiology)IncidenceHazard ratioDiabetesMiddle AgedCardiovascular diseaseCardiovascular DiseasesCohortFemaleCohort studymedicine.medical_specialty03 medical and health sciencesDiabetes mellitusInternal medicinemedicineHumansEgg consumptionAgedProportional Hazards ModelsProportional hazards modelbusiness.industryPREDIMED studymedicine.diseaseEndocrinologyDiabetes Mellitus Type 2Patient ComplianceSelf ReportbusinessDiabetic AngiopathiesFollow-Up Studies
researchProduct

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine ther…

2013

Background: Due to the limited data available in literature, the aim of this multi-centre study was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up of 18 months. Methods: Among the first 1135 TM patients in the MIOT (Myocardial Iron Overload in Thalassemia) network, we evaluated those who had received either combined regimen (DFO + DFP, N=51) or DFP (N=39) and DFO (N=74) monotherapies between the two CMR scans. Iron overload was measured by T2* multiecho technique. Biventricular function parameters were qua…

MaleLiver Iron ConcentrationTime FactorsThalassemiaVentricular Function Leftchemistry.chemical_compoundMedicineDeferiproneProspective StudiesMedicine(all)Ejection fractionRadiological and Ultrasound TechnologyBeta thalassemiaDeferoxamineTreatment OutcomeItalyLiverCardiologyThalassemiaDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineDeferiproneCardiomyopathiesmedicine.drugAdultmedicine.medical_specialtyCombination therapyPyridonesChelation therapyMagnetic Resonance Imaging CineDeferoxamineIron Chelating AgentsYoung AdultPredictive Value of TestsInternal medicineHumansRadiology Nuclear Medicine and imagingChelation therapyAnalysis of VarianceChi-Square Distributionbusiness.industryResearchMyocardiumbeta-ThalassemiaStroke Volumemedicine.diseaseSurgerychemistryVentricular Function RightCardiovascular magnetic resonancebusinessJournal of Cardiovascular Magnetic Resonance
researchProduct

Familial fatal fetal cardiomyopathy with isolated myocardial calcifications: A new syndrome?

2001

We describe three male sib fetuses with isolated myocardial calcifications resulting in intrauterine fetal death (IUFD) as early as the second trimester. No evidence for an underlying mitochondrial cytopathy, dystrophinopathy or myopathy was found. There were no signs of inflammation or a metabolic disorder, and the mother had no prenatal exposure of teratogenic drugs. Furthermore, no mutation in the Barth syndrome gene (G4.5) could be detected. Because isolated calcification of the heart and IUFD are not typical of any previously described inherited cardiomyopathy, it may represent a new familial fetal cardiomyopathy.

MaleMyocardial calcificationPathologymedicine.medical_specialtyHeart diseaseCardiomyopathyUltrasonography PrenatalFatal OutcomeFetusPregnancymedicineHumansMyopathyFetal DeathGenetics (clinical)Family HealthFetusbusiness.industryMyocardiumMetabolic disorderCalcinosisBarth syndromeSyndromemedicine.diseasePregnancy ComplicationsFetal DiseasesPregnancy Trimester Secondembryonic structuresFemalemedicine.symptomCardiomyopathiesbusinessCalcificationAmerican Journal of Medical Genetics
researchProduct

Interferon-γ Induces Chronic Active Myocarditis and Cardiomyopathy in Transgenic Mice

2007

Chronic heart failure is associated with an activation of the immune system characterized among other factors by the cardiac synthesis and serum expression of proinflammatory cytokines. There is unequivocal clinical and experimental evidence that the cytokine tumor necrosis factor-alpha is involved in the development of chronic heart failure, but a putative cardiotoxic potential of the proinflammatory cytokine interferon (IFN)-gamma remains primarily unknown. To investigate this issue we analyzed the cardiac phenotype of SAP-IFN-gamma transgenic mice, which constitutively express IFN-gamma in their livers and hence exhibit high circulating serum levels of this cytokine. SAP-IFN-gamma mice s…

MaleMyocarditismedicine.medical_treatmentT-LymphocytesCardiomyopathyGene ExpressionMice Inbred StrainsMice Transgenic030204 cardiovascular system & hematologyBiologyPathology and Forensic MedicineProinflammatory cytokine03 medical and health sciencesInterferon-gammaMice0302 clinical medicinemedicineAnimalsHumansInterferon gammaIntestinal MucosaPromoter Regions Genetic030304 developmental biology0303 health sciencesCardiotoxicityReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaMacrophagesHeartDendritic Cellsmedicine.diseaseInterleukin-123. Good healthRatsIntestinesMice Inbred C57BLMyocarditisSerum Amyloid P-ComponentCytokineEchocardiographyImmunologyChronic DiseaseInterleukin 12Tumor necrosis factor alphaFemaleCardiomyopathiesmedicine.drugRegular Articles
researchProduct